Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Anergis Starts European Phase IIb Clinical Trial with AllerT


Anergis Starts European Phase IIb Clinical Trial with AllerT in Patients with Moderate to Severe Allergy to Birch Pollen

- First patient treated with novel allergy vaccine -

EPALINGES, Switzerland – November 6, 2012 – Anergis, a company developing breakthrough allergy vaccines for fast and safe allergen-specific immunotherapy, reported today that it has treated the first patient in a large, well-controlled Phase IIb clinical trial in individuals with birch pollen allergy. The trial is designed to evaluate the efficacy and tolerability of a 5-injection / 2- months treatment with Anergis´ lead allergy vaccine, AllerT.

The multicentre, double-blind, placebo-controlled, randomized trial called AN004T was designed in collaboration with an International Steering Committee of experts with comprehensive experience in the design and conduct of allergen-specific immunotherapy trials(1). The trial will enroll about 300 patients with moderate to severe birch pollen allergy from up to 30 trial centers throughout Europe. Trial centers are located in Denmark, France, Latvia, Lithuania, Poland, Sweden and Switzerland. AN004T will evaluate the efficacy and safety of two doses of AllerT in comparison with placebo. The first patient was randomized and treated on November 3rd, 2012, in Vilnius, Lithuania.

As recommended by the European Guideline on the Clinical Development of Products for Specific Immunotherapy for the Treatment of Allergic Diseases (CHMP/EWP/18504/2006), the efficacy of AllerT will be assessed using a combined symptom and medication score as primary endpoint of the trial (combined Rhinoconjunctivitis Symptom and Medication Score RSMS). RSMS assessment is based on allergy symptom and medication data reported through electronic diaries by the trial subjects during the 2013 birch pollen season. Secondary and exploratory endpoints will include other clinical parameters related to symptoms and/or medications taken for allergy, as well as quality of life and immunological marker assessments.

“This clinical Phase IIb trial with AllerT is conducted according to the most up-to-date regulatory requirements for allergen-specific immunotherapy clinical trials,” said Vincent Charlon, CEO of Anergis. “With clinical efficacy assessments based on combined symptom and medication scores under real-life conditions during the birch pollen season, the trial will provide the most relevant efficacy data for the design of the Phase III trials and the future registration of AllerT.”

###
______________________________________________

Members of the AllerT Steering Committee are Prof. Dr. Frédéric De Blay (Hopitaux Universitaires de Strasbourg, France), Dr. Lars Jacobsen (Allergy Learning and Consulting, Denmark), Prof. Dr. Marek Jutel (Wroclaw Medical University, Poland), Prof. Dr. François Spertini (Centre Hospitalier Universitaire Vaudois, Switzerland) and Prof. Dr. Margitta Worm (Charité Universitätsmedizin Berlin, Germany)

About Anergis

Anergis SA is a Swiss-based biopharmaceutical company specializing in the discovery and development of novel allergy vaccines targeting the most frequent allergies. Anergis´ vaccines are based on its proprietary Continuous Overlapping Peptides technology. Allergies are the most prevalent and the fastest growing chronic conditions in the industrialized world, with over 300 million people affected.

Anergis’ lead-product AllerT, a vaccine to treat birch pollen allergies, is in Phase II clinical development. AllerR, its second vaccine candidate for the treatment of patients with allergy to ragweed pollen, has recently reached important preclinical milestones and received positive feedback from the U.S. FDA for the subsequent clinical development program in June 2012. Anergis has raised over CHF 20 million from Vinci Capital, Sunstone Capital, BioMedInvest and other investors including Esperante Ventures and Defi Gestion.

About Anergis´ Contiguous Overlapping Peptides Technology (COPs)

The only curative therapy of allergies available today, known as “desensitization” or “Specific Immunotherapy” (SIT), is a process of induction of tolerance to the allergen requiring 3-5 years of treatment and exposing patients to the risk of serious side effects. Anergis has developed a next-generation concept of SIT: vaccines based on COPs (Contiguous Overlapping Peptides), which reproduce the full-length amino acid sequence of the allergen in separate long peptides. COPs do not cross-react with IgE, the antibody class responsible for eliciting allergic hypersensitivity. Therefore, COPs can be safely administered at high doses to induce tolerance to the allergen after few injections only. Studies of COPs targeting bee venom and birch pollen allergies in both animals and humans have demonstrated excellent safety (no immediate allergic reaction) and immunogenicity (production of specific antibodies and cytokines against the original allergen and establishment of a long term immune memory).


Contact:
Anergis SA
CH-1066 Epalinges
Vincent Charlon, CEO
info@anergis.ch


Media Inquiries:

akampion
Dr. Ludger Wess, Ines Regina Buth
Managing Partners
Tel. +49 40 88165964 or +49 30 2363 2768
info@akampion.com


Publisher Contact Information:

Anergis
-
info@anergis.ch

Company profile of Anergis
Past press releases of Anergis.

Data


26,152
Tech investments
From our Online Data Service
16,897
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Sep 20€8.0MSecurity
Sep 20€3.0MArtificial Intelligence
Sep 20€55.0MInternet services
Sep 20€1.0MContent management
Sep 19€23.0MKnowledge management
Sep 19€2.3MKnowledge management
Sep 19€15.0MDiagnostics

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.